Home    Back

Gsk1070806    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
56Behcet disease1
96Crohn disease2

56. Behcet disease    [ 68 clinical trials,   87 drugs,   (DrugBank: 31 drugs),   36 drug target genes,   113 drug target pathways]
Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 68 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03522662
(ClinicalTrials.gov)		August 1, 20181/5/2018Anti IL-18 (GSK1070806) in Behcet's DiseaseAn Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's DiseaseBehcet's DiseaseDrug: GSK1070806Cambridge University Hospitals NHS Foundation TrustNULLUnknown status18 YearsN/AAll12Phase 2United Kingdom

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03681067
(ClinicalTrials.gov)		February 20, 201920/8/2018A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's DiseaseA Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients With Moderate-to-Severe Crohn's DiseaseCrohn DiseaseDrug: GSK1070806;Drug: Placebo- sodium chlorideUniversity of BirminghamGlaxoSmithKline;University Hospital BirminghamRecruiting16 YearsN/AAll30Phase 1;Phase 2United Kingdom
2EUCTR2018-002001-65-GB
(EUCTR)		13/12/201801/10/2018A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s DiseaseA Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients with Moderate-to-Severe Crohn’s Disease - CDAID GSK1070806 Crohn's disease
MedDRA version: 20.0;Level: LLT;Classification code 10013099;Term: Disease Crohns;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		University of BirminghamNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		36Phase 1United Kingdom